Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin 2, Dublin, Ireland.
Mol Cancer. 2012 Feb 5;11:6. doi: 10.1186/1476-4598-11-6.
Protein tyrosine phosphatase receptor delta (PTPRD) is a member of a large family of protein tyrosine phosphatases which negatively regulate tyrosine phosphorylation. Neuroblastoma is a major childhood cancer arising from precursor cells of the sympathetic nervous system which is known to acquire deletions and alterations in the expression patterns of PTPRD, indicating a potential tumor suppressor function for this gene. The molecular mechanism, however, by which PTPRD renders a tumor suppressor effect in neuroblastoma is unknown.
As a molecular mechanism, we demonstrate that PTPRD interacts with aurora kinase A (AURKA), an oncogenic protein that is over-expressed in multiple forms of cancer, including neuroblastoma. Ectopic up-regulation of PTPRD in neuroblastoma dephosphorylates tyrosine residues in AURKA resulting in a destabilization of this protein culminating in interfering with one of AURKA's primary functions in neuroblastoma, the stabilization of MYCN protein, the gene of which is amplified in approximately 25 to 30% of high risk neuroblastoma.
PTPRD has a tumor suppressor function in neuroblastoma through AURKA dephosphorylation and destabilization and a downstream destabilization of MYCN protein, representing a novel mechanism for the function of PTPRD in neuroblastoma.
蛋白酪氨酸磷酸酶受体 δ(PTPRD)是蛋白酪氨酸磷酸酶大家族的一员,其可负向调节酪氨酸磷酸化。神经母细胞瘤是一种起源于交感神经系统前体细胞的主要儿童期癌症,已知其会发生 PTPRD 的缺失和表达模式改变,表明该基因可能具有肿瘤抑制功能。然而,PTPRD 在神经母细胞瘤中发挥肿瘤抑制作用的分子机制尚不清楚。
作为一种分子机制,我们证明 PTPRD 与极光激酶 A(AURKA)相互作用,AURKA 是一种在多种癌症中过度表达的致癌蛋白,包括神经母细胞瘤。神经母细胞瘤中 PTPRD 的异位上调使 AURKA 的酪氨酸残基去磷酸化,导致该蛋白不稳定,最终干扰 AURKA 在神经母细胞瘤中的主要功能之一,即稳定 MYCN 蛋白的基因,大约 25%至 30%的高危神经母细胞瘤存在 MYCN 基因扩增。
PTPRD 通过 AURKA 去磷酸化和失稳以及下游 MYCN 蛋白失稳在神经母细胞瘤中发挥肿瘤抑制功能,代表了 PTPRD 在神经母细胞瘤中功能的一种新机制。